Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56,078,244
-
Total 13F shares
-
40,656,241
-
Share change
-
-7,084,519
-
Total reported value
-
$63,018,032
-
Put/Call ratio
-
82%
-
Price per share
-
$1.55
-
Number of holders
-
83
-
Value change
-
-$11,756,465
-
Number of buys
-
31
-
Number of sells
-
44
Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q1 2025
As of 31 Mar 2025,
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by
83 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,656,241 shares.
The largest 10 holders included
T. Rowe Price Investment Management, Inc., Vestal Point Capital, LP, NEA Management Company, LLC, BlackRock, Inc., Bellevue Group AG, VANGUARD GROUP INC, TANG CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, Siren, L.L.C., and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
83
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.